Studybox Research 510(k) Clinical Studies
Syphilis Rapid Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Syphilis incidence in the United States rose sharply over the past decade, including congenital syphilis, and same-visit treponemal testing has an obvious role. The clinical study is a serology comparison with a complication: treponemal antibodies persist for life in most people after treatment, so a reactive result cannot distinguish active from past infection. Study subjects must be characterized by stage and treatment history, and the labeling will describe the test as an aid to diagnosis requiring confirmatory and nontreponemal follow-up.
Sensitivity in primary syphilis is lower for all treponemal tests because antibodies are still developing, and this stage is where a rapid test has the most clinical value and the fewest study subjects. Enrollment typically relies on sexual health clinics and emergency departments with high syphilis volume, supplemented with characterized banked sera for staging strata that are hard to enroll prospectively.
- Analyte
- Treponema pallidum antibodies (treponemal), with some devices adding a nontreponemal component
- Therapeutic area
- STD/STI Detection
- Specimens
- Capillary Fingerstick Blood, Venous Whole Blood, Serum and Plasma
- Intended-use settings
- urgent care, physician office, pharmacy, emergency department
- Operators
- Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- Performance is reported by stage; primary syphilis sensitivity is typically the weakest and most-examined cell, and banked characterized sera are commonly used to fill it, with the retrospective arm reported separately.
- For purely treponemal devices, other treponemal and spirochetal infections are the relevant cross-reactivity question; if the device adds a nontreponemal component, conditions known to cause nontreponemal false positives (pregnancy, autoimmune disease) belong in the specificity population.
- Each specimen type claimed needs its own comparison; matrix equivalence studies may support serum and plasma when fingerstick carries the clinical study.
Endpoints the study must support
- Sensitivity by disease stage (primary, secondary, early latent, late latent, previously treated) against the laboratory treponemal reference, with 95% confidence intervals
- Specificity in a low-prevalence population without history of syphilis
- Agreement across claimed specimen types (fingerstick, venous whole blood, serum, plasma)
- Invalid rate and inter-operator agreement in waived settings
Enrollment realities
Driven by prospectively enrolled primary and secondary syphilis cases, which are uncommon even at high-volume clinics; banked staged sera are typically needed. Specificity enrollment at low-prevalence waived sites accrues quickly.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Syphilis Rapid Test Study Questions.
01 Who operates the syphilis rapid test in a 510(k) studies study?
Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a syphilis rapid test study?
Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.
03 What drives enrollment for a syphilis rapid test study?
Driven by prospectively enrolled primary and secondary syphilis cases, which are uncommon even at high-volume clinics; banked staged sera are typically needed. Specificity enrollment at low-prevalence waived sites accrues quickly.
Let's talk IVD research
Planning a syphilis rapid test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.